<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01901809</url>
  </required_header>
  <id_info>
    <org_study_id>NA 00083629</org_study_id>
    <nct_id>NCT01901809</nct_id>
  </id_info>
  <brief_title>Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>ROPA-DOP</acronym>
  <official_title>Randomized Evaluation of Heart Failure With Preserved Ejection Fraction (HFpEF) Patients With Acute Heart Failure and Dopamine (ROPA-DOP) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart Failure with preserved Ejection Fraction (HFPEF) accounts for 40-50% of all heart
      failure patients with a frequency of hospital admissions for acute decompensation and short
      and long term mortality similar to patients with heart failure with reduced ejection fraction
      (HFREF). Patients with HFPEF are often preload dependent and despite admission to the
      hospital for acute decompensated heart failure (ADHF), are typically difficult to diurese due
      to the development of acute kidney injury. No studies have been performed evaluating
      treatment strategies for these patients. The investigators hypothesize that changing the
      method of diuresis and/or the addition of low-dose dopamine for the treatment of ADHF in
      patients with HFPEF will reduce renal injury, resulting in a shorter length of stay, and
      decrease hospital readmissions over the ensuing year. This trial will randomize patients to
      either bolus or continuous infusion furosemide and then to either dopamine or no dopamine.
      The primary endpoint will be renal function at 72 hours as measured by change in Glomerular
      Filtration Rate (GFR). Secondary endpoints for readmission, functional capacity, quality of
      life, and amount of diuresis will also be collected.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2013</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Serum Creatinine at 72 Hours.</measure>
    <time_frame>72 hours</time_frame>
    <description>Percent change in serum creatinine from randomization to 72 hrs from treatment protocol initiation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in Serum Creatinine at 72 Hours - Continuous vs Intermittent Diuretic</measure>
    <time_frame>72 hours</time_frame>
    <description>Percent change in serum creatinine from randomization to 72 hrs from treatment protocol initiation by diuretic strategy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in Serum Creatinine at 72 Hours - Dopamine vs No Dopamine</measure>
    <time_frame>72 hours</time_frame>
    <description>Percent change in serum creatinine from randomization to 72 hrs from treatment protocol initiation by dopamine strategy</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Heart Failure, Diastolic</condition>
  <arm_group>
    <arm_group_label>Bolus furosemide and no dopamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>If the patient is not on a prior diuretic dose, a standard dose of furosemide 40mg IV every 12 hrs, with total dose of 80 mg IV over 24 hrs will be initiated.
If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose every 12 hrs. (i.e if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose will be furosemide 80mg IV twice daily).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous infusion furosemide and no dopamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>If the patient is not on a prior diuretic dose, a standard dose of furosemide 80mg IV over 24 hrs, will be initiated.
If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose continuously over 24 hrs. . (i.e. if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose would be furosemide 160mg IV to be administered continuously over 24 hrs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bolus furosemide plus dopamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intermittent furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous furosemide plus dopamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <arm_group_label>Bolus furosemide and no dopamine</arm_group_label>
    <arm_group_label>Continuous infusion furosemide and no dopamine</arm_group_label>
    <arm_group_label>Bolus furosemide plus dopamine</arm_group_label>
    <arm_group_label>Continuous furosemide plus dopamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dopamine</intervention_name>
    <arm_group_label>Bolus furosemide plus dopamine</arm_group_label>
    <arm_group_label>Continuous furosemide plus dopamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission to Johns Hopkins Hospital for acute decompensated heart failure.

          -  Patient ≥18 years of age

          -  Estimated GFR of &gt; 15 milliliters/min/1.73m2 determined by the Modification of Diet in
             Renal Disease (MDRD) equation

          -  Willingness to provide informed consent

          -  Known ejection fraction by noninvasive testing of &gt; 50% within 12 months of admission
             to the hospital with no interval myocardial infarction since inclusion transthoracic
             echo, by history, or by ECG.

          -  Negative pregnancy test in a female of child bearing potential

          -  Willingness of primary attending physician for patient to participate.

        Exclusion Criteria:

          -  Systolic BP &lt;90 mmHg on admission

          -  Hemoglobin (Hgb) &lt; 8 g/dl

          -  Known allergy or intolerance to furosemide or low dose dopamine.

          -  Hemodynamically significant arrhythmias including ventricular tachycardia or
             defibrillator shock within 4 weeks

          -  Acute coronary syndrome within 4 weeks

          -  Cardiac diagnoses in addition to or other than HFpEF:

             i. Active myocarditis ii. Hypertrophic obstructive cardiomyopathy iii. Severe valvular
             disease iv. Restrictive or constrictive cardiomyopathy, including known amyloidosis,
             sarcoidosis, hemachromatosis v. Complex congenital heart disease vi. Constrictive
             pericarditis vii. Severe pulmonary hypertension (RVSP ≥ 60), not secondary to HFpEF

          -  Non-cardiac pulmonary edema

          -  Clinical evidence of digoxin toxicity

          -  Received IV vasoactive treatment or ultra-filtration therapy for heart failure since
             initial presentation

          -  Anticipated need for IV vasoactive treatment or ultra-filtration for heart failure
             during this hospitalization

          -  History of temporary or permanent renal replacement therapy or ultrafiltration

          -  History of renal artery stenosis &gt; 50%

          -  Need for mechanical hemodynamic support

          -  Sepsis

          -  Terminal illness (other than HF) with expected survival of less than 1 year

          -  Previous adverse reaction to the study drugs

          -  Use of IV iodinated contrast material/dye in last 72 hours or planned during
             hospitalization

          -  Enrollment or planned enrollment in another randomized clinical trial during this
             hospitalization

          -  Inability to comply with planned study procedures

          -  Pregnancy or nursing mothers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart D Russell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>July 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2013</study_first_posted>
  <results_first_submitted>April 18, 2018</results_first_submitted>
  <results_first_submitted_qc>April 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2018</results_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure, diastolic</keyword>
  <keyword>HFpEF</keyword>
  <keyword>Diuretics</keyword>
  <keyword>Dopamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bolus Furosemide</title>
          <description>If the patient is not on a prior diuretic dose, a standard dose of furosemide 40mg IV every 12 hrs, with total dose of 80 mg IV over 24 hrs will be initiated.
If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose every 12 hrs. (i.e if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose will be furosemide 80mg IV twice daily).
Furosemide</description>
        </group>
        <group group_id="P2">
          <title>Continuous Infusion Furosemide</title>
          <description>If the patient is not on a prior diuretic dose, a standard dose of furosemide 80mg IV over 24 hrs, will be initiated.
If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose continuously over 24 hrs. . (i.e. if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose would be furosemide 160mg IV to be administered continuously over 24 hrs).
Furosemide</description>
        </group>
        <group group_id="P3">
          <title>Bolus Furosemide Plus Dopamine</title>
          <description>Intermittent furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min administered as an infusion.
Furosemide
Dopamine</description>
        </group>
        <group group_id="P4">
          <title>Continuous Furosemide Plus Dopamine</title>
          <description>Continuous furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min administered as an infusion.
Furosemide
Dopamine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bolus Furosemide</title>
          <description>If the patient is not on a prior diuretic dose, a standard dose of furosemide 40mg IV every 12 hrs, with total dose of 80 mg IV over 24 hrs will be initiated.
If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose every 12 hrs. (i.e if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose will be furosemide 80mg IV twice daily).
Furosemide</description>
        </group>
        <group group_id="B2">
          <title>Continuous Infusion Furosemide</title>
          <description>If the patient is not on a prior diuretic dose, a standard dose of furosemide 80mg IV over 24 hrs, will be initiated.
If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose continuously over 24 hrs. . (i.e. if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose would be furosemide 160mg IV to be administered continuously over 24 hrs).
Furosemide</description>
        </group>
        <group group_id="B3">
          <title>Bolus Furosemide Plus Dopamine</title>
          <description>Intermittent furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min administered as an infusion.
Furosemide
Dopamine</description>
        </group>
        <group group_id="B4">
          <title>Continuous Furosemide Plus Dopamine</title>
          <description>Continuous furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min administered as an infusion.
Furosemide
Dopamine</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="13"/>
                    <measurement group_id="B2" value="63" spread="10"/>
                    <measurement group_id="B3" value="66" spread="15"/>
                    <measurement group_id="B4" value="67" spread="13"/>
                    <measurement group_id="B5" value="66" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Serum Creatinine at 72 Hours.</title>
        <description>Percent change in serum creatinine from randomization to 72 hrs from treatment protocol initiation.</description>
        <time_frame>72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bolus Furosemide and no Dopamine</title>
            <description>If the patient is not on a prior diuretic dose, a standard dose of furosemide 40mg IV every 12 hrs, with total dose of 80 mg IV over 24 hrs will be initiated.
If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose every 12 hrs. (i.e if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose will be furosemide 80mg IV twice daily).
Furosemide</description>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion Furosemide and no Dopamine</title>
            <description>If the patient is not on a prior diuretic dose, a standard dose of furosemide 80mg IV over 24 hrs, will be initiated.
If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose continuously over 24 hrs. . (i.e. if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose would be furosemide 160mg IV to be administered continuously over 24 hrs).
Furosemide</description>
          </group>
          <group group_id="O3">
            <title>Bolus Furosemide Plus Dopamine</title>
            <description>Intermittent furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min
Furosemide
Dopamine</description>
          </group>
          <group group_id="O4">
            <title>Continuous Furosemide Plus Dopamine</title>
            <description>Continuous furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min
Furosemide
Dopamine</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Serum Creatinine at 72 Hours.</title>
          <description>Percent change in serum creatinine from randomization to 72 hrs from treatment protocol initiation.</description>
          <units>percent change in serum creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="22"/>
                    <measurement group_id="O2" value="11" spread="21"/>
                    <measurement group_id="O3" value="5" spread="17"/>
                    <measurement group_id="O4" value="20" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Serum Creatinine at 72 Hours - Continuous vs Intermittent Diuretic</title>
        <description>Percent change in serum creatinine from randomization to 72 hrs from treatment protocol initiation by diuretic strategy</description>
        <time_frame>72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bolus Furosemide</title>
            <description>If the patient is not on a prior diuretic dose, a standard dose of furosemide 40mg IV every 12 hrs, with total dose of 80 mg IV over 24 hrs will be initiated.
If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose every 12 hrs. (i.e if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose will be furosemide 80mg IV twice daily).</description>
          </group>
          <group group_id="O2">
            <title>Continuous Infusion Furosemide</title>
            <description>If the patient is not on a prior diuretic dose, a standard dose of furosemide 80mg IV over 24 hrs, will be initiated.
If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose continuously over 24 hrs. . (i.e. if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose would be furosemide 160mg IV to be administered continuously over 24 hrs).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Serum Creatinine at 72 Hours - Continuous vs Intermittent Diuretic</title>
          <description>Percent change in serum creatinine from randomization to 72 hrs from treatment protocol initiation by diuretic strategy</description>
          <units>percent change in serum creatinine</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="-1.1" upper_limit="10.4"/>
                    <measurement group_id="O2" value="16" lower_limit="8.5" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>11.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.0</ci_lower_limit>
            <ci_upper_limit>20.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Serum Creatinine at 72 Hours - Dopamine vs No Dopamine</title>
        <description>Percent change in serum creatinine from randomization to 72 hrs from treatment protocol initiation by dopamine strategy</description>
        <time_frame>72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dopamine</title>
            <description>Diuretic therapy plus addition of dopamine at 3 µg/kg/min administered as an infusion.</description>
          </group>
          <group group_id="O2">
            <title>No Dopamine</title>
            <description>Diuretic therapy only</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Serum Creatinine at 72 Hours - Dopamine vs No Dopamine</title>
          <description>Percent change in serum creatinine from randomization to 72 hrs from treatment protocol initiation by dopamine strategy</description>
          <units>percent change in serum creatinine</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="1.4" upper_limit="14.6"/>
                    <measurement group_id="O2" value="12.8" lower_limit="5.7" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.4</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bolus Furosemide</title>
          <description>If the patient is not on a prior diuretic dose, a standard dose of furosemide 40mg IV every 12 hrs, with total dose of 80 mg IV over 24 hrs will be initiated.
If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose every 12 hrs. (i.e if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose will be furosemide 80mg IV twice daily).
Furosemide</description>
        </group>
        <group group_id="E2">
          <title>Continuous Infusion Furosemide</title>
          <description>If the patient is not on a prior diuretic dose, a standard dose of furosemide 80mg IV over 24 hrs, will be initiated.
If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose continuously over 24 hrs. . (i.e. if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose would be furosemide 160mg IV to be administered continuously over 24 hrs).
Furosemide</description>
        </group>
        <group group_id="E3">
          <title>Bolus Furosemide Plus Dopamine</title>
          <description>Intermittent furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min administered as an infusion.
Furosemide
Dopamine</description>
        </group>
        <group group_id="E4">
          <title>Continuous Furosemide Plus Dopamine</title>
          <description>Continuous furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min administered as an infusion.
Furosemide
Dopamine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed. The investigator team was blinded to study assignment; however, the patient and treating physicians were un-blinded.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kavita Sharma, MD</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-955-7670</phone>
      <email>ksharma8@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

